Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06561620 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

Name: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients — clinical trial record (NCT06561620)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorFudan University

Started2024-05-01

View on ClinicalTrials.gov ↗

Amendment history

2024-08-20

Study Identification, Study Status v1

Study title-1 characters

Befotertinib Adjuvant Therapy in Stage IA2-~~III~~IB NSCLC Patients

2024-08-16

Original filing

Fudan University

624 trials monitored

See 9 trials at risk

To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).

Trial Details

NCT Number	NCT06561620
Lead Sponsor	Fudan University
Conditions	3-year Disease-free Survival
Enrollment	592 participants
Start Date	2024-05-01
Primary Completion	2027-05-01 (estimated)
Study Completion	2029-05-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-22